Jesús Delgado‐Calle

Federal Grant PI High Impact

Assistant Professor

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

JDelgadocalle@uams.edu

30 h-index 192 pubs 3,554 cited

Research Areas

Links

ORCID Lab Website

OverviewAI-generated summary

Jesús Delgado‐Calle's research focuses on the role of osteocytes in bone health and disease, particularly in the context of multiple myeloma and cancer metastasis. He investigates how osteocytes, a type of bone cell, act as signaling hubs that can influence tumor growth and bone destruction. His work also explores the mechanisms by which cancer cells and osteocytes interact within the bone marrow niche, contributing to disease progression.

Delgado‐Calle has received significant federal funding from the NIH/National Cancer Institute to support his investigations. One grant, totaling $454,799, is dedicated to understanding the contribution of osteocytes to the musculoskeletal effects of multiple myeloma. Another grant, for $918,404, supports research into bone-targeted therapies aimed at improving bone health and preventing relapse in patients with multiple myeloma. His research network includes extensive collaboration with colleagues at the University of Arkansas for Medical Sciences, such as Hayley M. Sabol, Teresita Bellido, Sharmin Khan, and Aric Anloague, with whom he has co-authored numerous publications.

His scholarly output includes a substantial number of publications (192) and citations (3,507), reflecting his active contributions to the field, as indicated by his h-index of 30 and his designation as a high-impact researcher. His recent publications address topics such as extrachromosomal circular DNA identification, the role of Notch signaling in myeloma and bone destruction, and the identification of senescent osteocytes in breast cancer metastasis.

Metrics

h-index: 30
Publications: 192
Citations: 3,554

Selected Publications

Paracrine activity of Smurf1-silenced mesenchymal stem cells enhances bone regeneration and reduces bone loss in postmenopausal osteoporosis (2025)

2 citations DOI OpenAlex
A novel CCL3-HMGB1 signaling axis regulating osteocyte RANKL expression in multiple myeloma (2024)

8 citations DOI OpenAlex
Single-Cell Transcriptomic Analysis Identifies Senescent Osteocytes That Trigger Bone Destruction in Breast Cancer Metastasis (2024)

14 citations DOI OpenAlex
Senolytics deplete senescent osteocytes and improve bone health in metastatic breast cancer (2024)

DOI OpenAlex
Single-cell Transcriptome Analysis Identifies Senescent Osteocytes as Contributors to Bone Destruction in Breast Cancer Metastasis (2024)

3 citations DOI OpenAlex
Osteocytes and Paget’s Disease of Bone (2024)

4 citations DOI OpenAlex
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma (2024)

10 citations DOI OpenAlex
Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma (2023)

5 citations DOI OpenAlex
Engineering a Pro-Osteogenic Secretome through the Transient Silencing of the Gene Encoding Secreted Frizzled Related Protein 1 (2023)

5 citations DOI OpenAlex
Osteocytes: New Kids on the Block for Cancer in Bone Therapy (2023)

15 citations DOI OpenAlex
Data from Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity (2023)

DOI OpenAlex
Editorial: The role of the bone marrow microenvironment in multiple myeloma evolution and therapy (2023)

3 citations DOI OpenAlex
CReSIL: accurate identification of extrachromosomal circular DNA from long-read sequences (2022)

50 citations DOI OpenAlex
Abstract 5672: Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction (2022)

DOI OpenAlex
Abstract 5675: Pathological crosstalk between osteocytes and breast cancer cells in bone metastasis (2022)

DOI OpenAlex